Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30225319 | 0.95 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDTSHRLMNA | |
| SCHEMBL23975658 | 0.95 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDTSHRLMNA | |
| SCHEMBL30225185 | 0.85 | HPGD (0.41) | ALDH1A1KDM4EHPGDHTR2CACHE | |
| SCHEMBL23975679 | 0.85 | HPGD (0.41) | ALDH1A1KDM4EHPGDHTR2CACHE | |
| SCHEMBL25529505 | 0.83 | HPGD (0.42) | ALDH1A1KDM4EHPGDHTR2CACHE | |
| SCHEMBL23493540 | 0.79 | HTR2C (0.51) | ALDH1A1TSHRLMNAHTR2CSMN1; SMN2 | |
| SCHEMBL2710619 | 0.78 | SMN1; SMN2 (0.40) | ALDH1A1KDM4EHPGDTSHRLMNA | |
| SCHEMBL2708151 | 0.78 | MTOR (0.45) | ALDH1A1KDM4EHPGDTSHRLMNA | |
| SCHEMBL26650736 | 0.78 | HRH4 (0.34) | ALDH1A1KDM4EHTR2C | |
| SCHEMBL1836812 | 0.78 | MTOR (0.50) | KDM4EHTR2CSMN1; SMN2HTR2BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028174-A1 | NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
| US-4352928-A | ANTIINFLAMMATORY, HYPOGLYCEMIC, ANTICOAGULANT, ANOREXIGENIC, SEROTONIN EFFEC | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1982-10-05 | — | — | US | disclosed |
| EP-0022481-A1 | 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions | Mitsubishi Yuka Pharmaceutical Co., Ltd. (JP) | 1981-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | GATAD2A, GATAD2B, RUNX1 | ALDH1A1 3621/4885KDM4E 309/4885HPGD 4556/4885 |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | ALDH1A1 3397/4885KDM4E 1225/4885HPGD 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.